Blood -- Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia

Blood, Vol. 113, Issue 3, 726-732, January 15, 2009

Donors with group B KIR haplotypes improve relapse-free survival after unrelated hematopoietic cell transplantation for acute myelogenous leukemia
Blood Cooley et al. 113: 726

Supplemental materials for: Cooley et al

Files in this Data Supplement:

Table S1. Effect of individual KIR genes on relapse-free survival and over-all survival after URD HCT (PDF, 21.2 KB) -
Shown are the relative risks (RR), 95% confidence intervals (CI) and p-values for the effect in donors of the presence (vs. absence) of each KIR gene on relapse-free survival (RFS) and overall survival (OS). The only KIR locus that is significant at a level of 0.05 for both RFS and OS is 2DS2 (present in 79% of the population). Although the analysis was not adjusted for multiple comparisons, similar results were obtained for KIR2DL2, which is in high linkage disequilibrium with KIR2DS2. KIR2DL5, the other inhibitory KIR associated with a better RR of RFS, was present in 52% of the cohort. The inhibitory KIR2DL3, which was associated with a significantly worse relative risk of RFS, is present in 90% of donors in this cohort.